Samsung Biologics

At a glance

Samsung Biologics filed 149 disclosures in the last 12 months, including 44 insider, 6 contract, 4 earnings, 2 5% holder, 2 issuance and 1 m&a. The most recent key filing was on Oct 30: Executive sold 2 sh on the market at an average ₩425,000, Oct 27.

Revenue for 2025 was ₩4.56T, up 30.3% on 2024. Operating margin was 45.4% against 37.8% a year earlier. Debt was 48% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.58T and operating profit of ₩1.17T.

The 2025 annual report lists 5,455 employees with an average tenure of 4.9 years and average pay of ₩114.3M, #109 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩1.3B each on average. It paid no cash dividend for 2025. 삼성물산 and related parties held 74.32% at year end.

From the 2025 annual report

Staff: 5,455 (3,026 men, 2,429 women), of whom 260 on fixed-term contracts. Total pay for the year: ₩610B. Directors and auditors: 7, paid ₩8.9B in total.

No cash dividend was paid for 2025.

Largest shareholder

삼성물산 holds 43.06%; with 5 related parties the group holds 74.32% of common shares at year end (from 74.34% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Rankings: Operating margin #9 of 1,376 · Director pay #14 of 2,157 · Employees #43 of 2,110

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 10% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary